Neuronetics, Inc. filings document the public reporting record for a Nasdaq-listed medical technology and healthcare company with common stock traded under STIM. Recent Form 8-K reports furnish operating results, investor presentation materials, executive appointments and retirements, compensation arrangements, restructuring charges, and material agreements tied to credit facilities and registration rights.
The company’s proxy materials describe annual meeting voting matters, director elections, auditor ratification, advisory executive compensation votes, and equity incentive plan approvals. Together with event reports, the filings disclose governance procedures, capital-structure matters, Nasdaq-listed security information, and contractual obligations associated with Neuronetics’ medical device and clinic-services operations.
Neuronetics, Inc. reported that executive Naor Nir, serving as EVP, CFO & Treasurer, submitted an initial statement of beneficial ownership on SEC Form 3. The structured data lists no equity transactions or holdings, and there are no derivative positions disclosed.
Neuronetics, Inc. announced executive leadership changes and related compensation arrangements. The Board appointed Nir Naor as Executive Vice President, Chief Financial Officer, and Treasurer, effective on or about July 23, 2026, under an offer letter providing a $480,000 base salary, a target annual bonus equal to 50% of base salary, and a grant of 500,000 Restricted Stock Units vesting over four years. If terminated without cause or if he resigns for good reason, he is entitled to 12 months of base salary, a prorated target bonus, and continued health coverage. The company also reported that W. Andrew Macan, Executive Vice President, Chief Legal Officer, and Corporate Secretary, will depart on August 15, 2026, receiving a retention bonus of $231,750, vesting of 164,361 RSUs, and a separation payment of $475,087.50 paid over 12 months; his departure is stated not to result from any dispute or disagreement.
Neuronetics, Inc. disclosed that large shareholder Jorey Chernett, a more than ten percent owner, made an open-market purchase of 35,000 shares of Common Stock on 2026-07-14 at a weighted average price of $1.78 per share, increasing his direct holdings to 10,588,988 shares. The shares were bought in multiple trades between $1.77 and $1.79.
Neuronetics, Inc. executive Cory Anderson, EVP & Gen. Manager, Greenbrook, filed an initial statement of beneficial ownership. He reports direct holdings of the company’s common stock and performance restricted stock units that can deliver up to 15,000 and 18,335 shares at a $0.0000 exercise price. These PRSUs vest between December 31, 2026 and December 31, 2027, contingent on specified Cash Balance and Cash Flow Breakeven performance metrics and his continued service.
Neuronetics, Inc. announced that its board of directors has promoted Cory Anderson to Executive Vice President, General Manager of Greenbrook, effective July 1, 2026. He moves from his prior role as Senior Vice President, Chief Technology Officer and brings over 25 years of medical device leadership experience.
In connection with the promotion, Anderson’s annual base salary will increase to $425,000, and his target discretionary annual cash bonus will be set at 45% of his then-current base salary. He will remain eligible for annual equity grants under the company’s long‑term incentive program and continues under existing indemnification, restrictive covenant, and severance agreements.
Neuronetics, Inc. director Avinash Amin reported internal share transfers among affiliated investment funds, with no open‑market buying or selling. On 2026-06-15, Amin transferred 4,634 shares of common stock to Madryn Health Partners II, LP, 34,932 shares to Madryn Health Partners II (Cayman Master), LP, and 2,934 shares to Madryn Select Opportunities, LP.
The footnotes state these transfers involved shares received as director compensation and were made for no consideration, as provided in each fund’s partnership agreement. After these J-code restructuring transactions, Amin directly holds 30,000 shares of Neuronetics common stock.
Neuronetics, Inc. insider filing reports internal share transfers among investment funds advised by Madryn Asset Management related to director compensation. On May 28 and June 15, entities associated with Madryn reallocated a total of 72,500 shares of common stock, all coded as other acquisitions or dispositions.
The shares originated from restricted stock units awarded to director Avinash Amin, which are held for the benefit of Madryn Health Partners II, Madryn Health Partners II (Cayman Master), and Madryn Select Opportunities under their partnership agreements. Each transfer was made for no consideration and reflects reallocations among these funds rather than open‑market trades.
After these transactions, indirect holdings reported include 2,269,073 shares for one Madryn fund, 17,104,530 shares for another, and 1,435,958 shares for a third. The reporting persons state that they may be deemed to beneficially own these shares through advisory and general partner roles, but each disclaims beneficial ownership except to the extent of any pecuniary interest.
STIM submitted a Form 144 notice reporting a proposed sale of 42,164 shares of Common Stock associated with restricted stock vesting. The filing lists a broker-dealer, Fidelity Brokerage Services LLC, and an intended transaction date of 06/08/2026. It also discloses prior sales of 46,289 shares on 03/19/2026 by Keith Sullivan.
Neuronetics, Inc. director Megan Rosengarten reported receiving an award of 30,000 restricted stock units of common stock. The RSU grant is a form of equity compensation and carries no cash exercise price.
The award vests on the earlier of May 28, 2027, or her Board-approved separation of service or a change in control of Neuronetics, in each case requiring her continuous service through that date. After this grant, she holds 170,890 shares and RSUs of Neuronetics common stock directly.
Neuronetics, Inc. director Glenn P. Muir received a grant of 30,000 restricted stock units (RSUs) of common stock at no cost. The RSU award vests on the earlier of May 28, 2027, or a Board-approved separation of service or change in control, subject to his continuous service.
Each RSU converts into one share of Neuronetics common stock when it vests. Following this equity award, Muir’s reported direct holdings increased to 401,816 shares of common stock.